Latest news with #SamSlutsky
Business Insider
27-07-2025
- Business
- Business Insider
LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR yesterday and set a price target of $101.00. The company's shares closed last Friday at $66.49. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Slutsky is a 4-star analyst with an average return of 11.7% and a 39.25% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Celldex. Currently, the analyst consensus on Abivax SA Sponsored ADR is a Strong Buy with an average price target of $79.29, a 19.25% upside from current levels. In a report released on July 24, Morgan Stanley also upgraded the stock to a Buy with a $71.00 price target. Based on Abivax SA Sponsored ADR's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.01 million and a GAAP net loss of $47.3 million. In comparison, last year the company earned a revenue of $2.33 million and had a GAAP net loss of $95.79 million
Yahoo
06-07-2025
- Business
- Yahoo
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 26, Sam Slutsky, an analyst from LifeSci Capital, maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the associated price target at $50. He based the rating on the notable market opportunity for the company's IMVT-1402 for the treatment of Graves' disease, which is a leading cause of hyperthyroidism and has considerable unmet medical need. A closeup of a scientist working with a microscope in a biotech laboratory. The disease impacts around a million patients in the US, and current treatments typically render a majority of patients uncontrolled or intolerant. Since alternative therapies for the disease also have considerable drawbacks, the analyst reasoned that IMVT-1402 has potential as a novel, disease-modifying therapy. It reduces pathogenic IgG autoantibodies to target the disease's root cause, and positive proof-of-concept data from a first-generation anti-FcRn supports the therapy's efficacy. The analyst further reasoned that feedback from key opinion leaders highlights the significant need and demand for such targeted treatments, painting a positive picture for Immunovant, Inc. (NASDAQ:IMVT). Apart from IMVT-1402's dual effects in Graves' disease and thyroid eye disease, the company's ongoing trials further support the optimistic rating. Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn). While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
